RXi Pharmaceuticals, Corp. (NASDAQ:RXII) Launches Into Dynamic Immuno-Oncology Arena, Stocks Take Leap on News

RXi Pharmaceuticals, Corp. (NASDAQ:RXII) secures an exclusive option to acquire MirImmune, Inc., expanding its reach into the “high-value” field of immune-oncology.

SAN FRANCISCO, CA–(Marketwired – November 15, 2016) – By securing an exclusive option to acquire MirImmune Inc., RXi Pharmaceuticals Corp. (RXII) has expanded its reach into the “high-value” field of immune-oncology, a move that has energized the company and prompted a pair of analysts to express optimism about RXi’s future.

Included in this article is: RXi Pharmaceuticals Corp.

Keith Markey of Griffin Securities called the RXi Pharmaceuticals Corp. acquisition option “an attractive opportunity” in a research report released following the Oct. 12 announcement.

“Given the interest in cellular immunotherapies and the proven ability of checkpoint inhibitors to enhance T cell activity, RXi’s relatively small investments may well pay off handsomely, particularly if the sd-rxRNA pretreatment obviates the need for expensive checkpoint inhibitors,” Markey wrote.

RXi’s self-delivering RNAi (sd-rxRNA) compounds have the ability to “‘silence’ or down-regulate the expression of a specific gene that may be overexpressed in a disease condition,” according to the company. Thus far, the partnership with MirImmune has shown in cell cultures that the technology can enhance inhibition of checkpoints such as PD-1, and has the potential to improve the efficacy of innovative immunotherapies such as CAR T-cells.

Continue reading this article: Agreement Launches RXi Pharmaceuticals into Dynamic Immuno-Oncology Arena

About Streetwise Reports — The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

DISCLOSURE:

RXi Pharmaceuticals Corp. is a billboard sponsor of Streetwise Reports. Streetwise Reports does not accept stock in exchange for its services. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

Original Source

rxi-pharmaceuticals-graph

Shares of RXi Pharmaceuticals, Corp. (NASDAQ:RXII) are actively moving +9.72% thus far today on the news and have traded in the range of $1.11 – 1.27 during the session.  A number of research firms have recently weighed in on the stock, providing future price targets. The covering firms currently have a consensus one-year price target of $8.00 on the stock.  This is according to brokerage analysts polled by Thomson Reuters First Call.  This is the average number from the individual targets provided by the firms.  Analysts are projecting earnings per share of $-0.22 for the next fiscal quarter.  For the current year, analysts are predicting earnings of $-1.25 per share according to First Call.

In looking at where the stock is trading on a technical level, the stock is trading -7.67% away from its 50-day moving average of $1.34.  Based on the most recent available data, the equity is -71.49% off of its 52-week high of $4.35 and +31.91% away from its 52-week low which is $0.94.

Are Shares of RXi Pharmaceuticals, Corp. (NASDAQ:RXII) Ready to Explode?  Sign up to our Newsletter to be the First to Know

Sign up to get our Free Penny Stock Picks Before the Street!

Today, the stock opened at $1.12 and the last bid at the time of writing stood at $1.24.  During the session thus far, the equity dipped down to $1.11 and touched $1.27 as the high point.  RXi Pharmaceuticals, Corp. (NASDAQ:RXII) has a market cap of $8.13M and has seen an average daily volume of 37,692 over the past three months.

Sign Up to Receive Breaking Alerts on Stocks That Are Primed to Make a Run in the Bar Below.

Sign up to get our Free Penny Stock Picks Before the Street!

Disclaimer: The advice provided on this website is general advice only. It has been prepared without taking into account your objectives, financial situation or needs. Before acting on this advice you should consider the appropriateness of the advice, having regard to your own objectives, financial situation and needs.  Where quoted, past performance is not indicative of future performance.

Related posts

Leave a Comment